Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Declines By 5.3%

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 1,790,000 shares, a drop of 5.3% from the January 15th total of 1,890,000 shares. Approximately 5.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 1.8 days.

Iterum Therapeutics Stock Performance

Iterum Therapeutics stock opened at $1.48 on Thursday. Iterum Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $3.02. The stock has a fifty day moving average of $1.65 and a two-hundred day moving average of $1.45. The company has a market capitalization of $51.18 million, a price-to-earnings ratio of -1.13 and a beta of 2.28.

Institutional Investors Weigh In On Iterum Therapeutics

Several hedge funds have recently made changes to their positions in ITRM. XTX Topco Ltd acquired a new stake in shares of Iterum Therapeutics during the third quarter worth $36,000. Apollon Financial LLC boosted its holdings in shares of Iterum Therapeutics by 11.3% during the fourth quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock worth $443,000 after purchasing an additional 25,500 shares during the last quarter. Lee Financial Co acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth $28,000. Sanctuary Advisors LLC acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth $35,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth $777,000. Institutional investors and hedge funds own 9.21% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.